Background:
Algal polysaccharide and oligosaccharide derivatives have been shown to possess a
variety of therapeutic potentials and drug delivery applications. Algal polysaccharides contain sulfated sugar
monomers derived from seaweed including brown, red, and green microalgae. Here, in this review, the recent
progress of algal polysaccharides’ therapeutic applications as anticancer agents, as well as underlying cellular and
molecular mechanisms was investigated. Moreover, recent progress in the structural chemistry of important polysaccharides
with anticancer activities were illustrated.
Methods:
Electronic databases including “Scopus”, “PubMed”, and “Cochrane library” were searched using the
keywords “cancer”, or “tumor”, or “malignancy” in title/abstract, along with “algae”, or “algal” in the whole text
until July 2018. Only English language papers were included.
Results:
The most common polysaccharides involved in cancer management were sulfated polysaccharides, Fucoidans,
Carageenans, and Ulvan from different species of algae that have been recognized in vitro and in vivo.
The underlying anticancer mechanisms of algal polysaccharides included induction of apoptosis, cell cycle arrest,
modulation of transduction signaling pathways, suppression of migration and angiogenesis, as well as activation
of immune responses and antioxidant system. VEGF/VEGFR2, TGFR/Smad/Snail, TLR4/ROS/ER, CXCL12/
CXCR4, TGFR/Smad7/Smurf2, PI3K/AKT/mTOR, PBK/TOPK, and β-catenin/Wnt are among the main cellular
signaling pathways which have a key role in the preventive and therapeutic effects of algal polysaccharides
against oncogenesis.
Conclusion:
Algal polysaccharides play a crucial role in the management of cancer and may be considered the
next frontier in pharmaceutical research. Further well-designed clinical trials are mandatory to evaluate the efficacy
and safety of algal polysaccharides in patients with cancer.